Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

#172 Biologically Similar but Competitively Not So? Economic Considerations of IP Litigation Settlements Involving Biosimilars

Under the U.S. Supreme Court case FTC v. Actavis (2013), antitrust analysis of “reverse settlements” […]